COURSES AND SEMINARS
Chairs: M. Aapro, CH - F. Cardoso, PT - H.S. Rugo, US
AIMS AND OBJECTIVES
This high-level programme will be developed over two residential courses that will be held in November 2013 and in May 2014. The contents have been tailored for trained oncologists in all disciplines related to breast cancer with the aim to provide an update on the state-of-the-art therapeutic options as well as an overview of the latest advances in the field.
Part I which will take place in 2013 has been designed with plenary lectures as well as meet-the-professor group sessions offering balanced and blended educational content. Sessions in leadership and presentation skills have been included, which were felt to be relevant in consideration of the profile of the perspective participants.
Best of the year
• Advances in breast cancer: Key messages in 2013
• Progress in supportive care
• Key messages from ABC2: Hot off the press
From science to clinical practice
• Druggable targets in breast cancer: Where are we today and where are we going?
• Bone-modifying agents: To use or not to use in early breast cancer?
The voice of the patient
• Lecture and discussion: How are patients empowered in your region?
Controversies and challenges in breast cancer treatment
• Breast cancer in young women: A challenge
• How to treat the relapsing ER+ HER2-negative patient?
• HER-2 positive breast cancer: The latest advances
Meet-the-expert - group sessions
• Practical guidance for the management of breast cancer patients
• Supportive and palliative care, quality of life, side-effect management
• How to ensure best patient outcomes in restrictive scenarios?
• Do’s and don’ts of publications and submitting papers to journals and how to choose the right journal
• Leadership skills
• Presentation skills
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Programme and Organisation
Ph: +39 02 85464525
Ph: +39 02 85464529
The official language will be English. No translation will be provided.
CONTINUING MEDICAL EDUCATION - CME
The application for European accreditation was granted 6 European Continuing Medical Education credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
The organisers bear no responsibility for untoward events in relation to the participation in the course. Participants are advised to take out their own personal and travel insurance coverage.
BCU part I will follow the Advanced Breast Cancer Second International Consensus Conference that will be held on 7-9 November 2013 in Lisbon. Further information on ABC2 is available at www.abc-lisbon.org. However, ABC2 and BCU are two independent events and separate registration/application are to be processed.
SHARING PROGRESS IN CANCER CARE
Sharing Progress in Cancer Care programme (SPCC) is a pioneering partnership between the European School of Oncology and some of the world’s leading pharmaceutical companies.
This programme is organised through unrestricted grants provided by Novartis Oncology and Genomic Health, sustaining members of the SPCC programme.
M. Aapro, Clinique de Genolier, Multidisciplinary Oncology Institute, Genolier, CH
B. Bauer, SDA Bocconi School of Management, Organization and Human Resources Management Department, Milan, IT
E. Bergsten Nordstrom, Europa Donna President, Stockholm, SE
G. Bianchini, San Raffaele Hospital,Dep. Medical Oncology, Milan, IT
F. Cardoso, Champalimaud Cancer Center, Breast Cancer Unit, lisbon, PT
L. Costa, Hospital Santa Maria, EPE, Oncology Service, Lisbon, PT
J. Gligorov, Hopitaux Universitaires Paris Est Tenon, Dept. of Medical Oncology, Paris, FR
M. Godfrey, 3 Monkeys Communications, London, UK
N. Harbeck, Hospital of the University of Munich (LMU), Breast Centre, Munich, DE
G. Jerusalem, Centre Hospitalier Universitaire du Sart-Tilman, Liege, BE
H.S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, Breast Oncology Clinical Trials Education, San Francisco, US
G.W. Sledge, Stanford University, Oncology Division, Stanford, US
|14:30 Welcome, introductions, meeting objectives|
|14:35 Feedback from previous courses|
Best of the year - part I
|14:40 Advances in breast cancer: Key messages in 2013 |
H.S. Rugo, US
|15:15 Progress in supportive care |
M. Aapro, CH
|15:55||From science to clinical practice|
|15:55 Druggable targets in breast cancer: Where are we today and where are we going? |
J. Gligorov, FR
|16:40 Bone-modifying agents: To use or not to use in early breast cancer? |
L. Costa, PT
|17:10||New directions: enhancing sensitivity to treatment in HR+ and/or HER2+ breast cancer (sponsored lecture) |
G. Jerusalem. BE
|Best of the year - part II|
|17:40 Key messages from ABC2: Hot off the press |
F. Cardoso, PT
|18:15||Wrap-up of day 1|
Meet-the-expert, breakout sessions 1 (4 groups, 2 topics)
Breakfast - Parallel sessions (2 groups, 2 topics)
Parallel sessions (2 groups, 2 topics)
Controversies and challenges in breast cancer treatment
|09:35 Breast cancer in young women: A challenge N. Harbeck, DE|
|10:05 How to treat the relapsing ER+ HER2-negative patient? J. Gligorov, FR|
|10:35 HER-2 positive breast cancer: The latest advances G.W. Sledge, US|
|11:20||The voice of the patient|
|11:20 Breast cancer advocacy in Europe E. Bergsten Nordstrom, SE|
|11:35 Discussion: How are patients empowered in your region? Chairs: F. Cardoso, PT and H.S. Rugo, US|
Use of genomics to determine therapy in early stage disease (sponsored lecture)
Meet-the-expert, breakout sessions 2 (4 groups, 2 topics)
|15:30||Bus transfer to the airport|